AAUM (Average Assets Under Management) of ₹9,023.03 Cr for Jul-Sep 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 73.5% | 74.0% | ▲ +0.5% |
| Healthcare Services | 21.1% | 21.1% | ● -0.1% |
| Retailing | 2.7% | 2.5% | ▼ -0.2% |
| Healthcare Equipment & Supplies | 0.0% | 0.4% | ▲ +0.4% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 74.0% | 74.0% | ● 0.0% |
| Healthcare Services | 21.1% | 20.3% | ▼ -0.8% |
| Retailing | 2.5% | 2.5% | ● +0.0% |
| Healthcare Equipment & Supplies | 0.4% | 0.5% | ▲ +0.1% |
Comparing Aug 2026 → Sep 2026
| # | Stock | Sector | Aug 2026 | Sep 2026 | Change |
|---|---|---|---|---|---|
| 1 | Dr. Reddy's Laboratories Limited ₹499.33 Cr |
Pharmaceuticals & Biotechnology | 4.93% | 5.45% | +0.52% |
| 2 | Mankind Pharma Limited ₹401.50 Cr |
Pharmaceuticals & Biotechnology | 4.09% | 4.38% | +0.29% |
| 3 | Abbott India Limited ₹213.06 Cr |
Pharmaceuticals & Biotechnology | 2.13% | 2.32% | +0.19% |
| 4 | Ajanta Pharma Limited ₹330.91 Cr |
Pharmaceuticals & Biotechnology | 3.47% | 3.61% | +0.14% |
| 5 | Dr. Lal Path Labs Limited ₹198.81 Cr |
Healthcare Services | 2.04% | 2.17% | +0.13% |
| 6 | Suraksha Diagnostic Ltd ₹138.48 Cr |
Healthcare Services | 1.39% | 1.51% | +0.12% |
| 7 | Emcure Pharmaceuticals Limited ₹124.53 Cr |
Pharmaceuticals & Biotechnology | 1.25% | 1.36% | +0.11% |
| 8 | Divi's Laboratories Limited ₹651.11 Cr |
Pharmaceuticals & Biotechnology | 7.00% | 7.10% | +0.10% |
| 9 | Akums Drugs and Pharmaceuticals Limited ₹110.63 Cr |
Pharmaceuticals & Biotechnology | 1.11% | 1.21% | +0.10% |
| 10 | Molbio Diagnostics Ltd. ₹49.78 Cr |
Healthcare Equipment & Supplies | 0.44% | 0.54% | +0.10% |
| # | Stock | Sector | Aug 2026 | Sep 2026 | Change |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical Industries Limited ₹1,072.95 Cr |
Pharmaceuticals & Biotechnology | 12.37% | 11.71% | -0.66% |
| 2 | Apollo Hospitals Enterprise Limited ₹448.12 Cr |
Healthcare Services | 5.15% | 4.89% | -0.26% |
| 3 | Lupin Limited ₹565.21 Cr |
Pharmaceuticals & Biotechnology | 6.43% | 6.17% | -0.26% |
| 4 | Max Healthcare Institute Limited ₹247.15 Cr |
Healthcare Services | 2.92% | 2.70% | -0.22% |
| 5 | Pfizer Limited ₹123.33 Cr |
Pharmaceuticals & Biotechnology | 1.57% | 1.35% | -0.22% |
| 6 | Thyrocare Technologies Limited ₹205.01 Cr |
Healthcare Services | 2.45% | 2.24% | -0.21% |
| 7 | GlaxoSmithKline Pharmaceuticals Limited ₹285.09 Cr |
Pharmaceuticals & Biotechnology | 3.31% | 3.11% | -0.20% |
| 8 | Fortis Healthcare Limited ₹103.65 Cr |
Healthcare Services | 1.29% | 1.13% | -0.16% |
| 9 | Cipla Limited ₹551.19 Cr |
Pharmaceuticals & Biotechnology | 6.09% | 6.01% | -0.08% |
| 10 | Biocon Limited ₹92.73 Cr |
Pharmaceuticals & Biotechnology | 1.09% | 1.01% | -0.08% |
36 stocks — Sep 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹1,072.95 Cr |
Pharmaceuticals & Biotechnology |
11.71%
|
|
| 2 |
₹651.11 Cr |
Pharmaceuticals & Biotechnology |
7.10%
|
|
| 3 |
₹565.21 Cr |
Pharmaceuticals & Biotechnology |
6.17%
|
|
| 4 |
₹551.19 Cr |
Pharmaceuticals & Biotechnology |
6.01%
|
|
| 5 |
₹499.33 Cr |
Pharmaceuticals & Biotechnology |
5.45%
|
|
| 6 |
₹448.12 Cr |
Healthcare Services |
4.89%
|
|
| 7 |
₹401.50 Cr |
Pharmaceuticals & Biotechnology |
4.38%
|
|
| 8 |
₹359.13 Cr |
Pharmaceuticals & Biotechnology |
3.92%
|
|
| 9 |
₹330.91 Cr |
Pharmaceuticals & Biotechnology |
3.61%
|
|
| 10 |
₹285.09 Cr |
Pharmaceuticals & Biotechnology |
3.11%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.